{"Symbol": "ALLR", "AssetType": "Common Stock", "Name": "Allarity Therapeutics Inc", "Description": "Allarity Therapeutics A / S develops various therapeutic candidates for the treatment of cancer using complementary drug-specific diagnostics (cDx) generated by its drug response prediction technology. The company is headquartered in Horsholm, Denmark.", "CIK": "1860657", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "24 SCHOOL STREET, BOSTON, MA, UNITED STATES, 02108", "OfficialSite": "https://www.allarity.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-06-30", "MarketCapitalization": "17283700", "EBITDA": "-17067000", "PERatio": "0.207", "PEGRatio": "None", "BookValue": "0.832", "DividendPerShare": "None", "DividendYield": "None", "EPS": "5.75", "RevenuePerShareTTM": "-0.018", "ProfitMargin": "0", "OperatingMarginTTM": "0", "ReturnOnAssetsTTM": "-0.41", "ReturnOnEquityTTM": "-1.506", "RevenueTTM": "-7127000", "GrossProfitTTM": "-36348000", "DilutedEPSTTM": "5.75", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0", "AnalystTargetPrice": "9.25", "AnalystRatingStrongBuy": "-", "AnalystRatingBuy": "-", "AnalystRatingHold": "-", "AnalystRatingSell": "-", "AnalystRatingStrongSell": "-", "TrailingPE": "0.207", "ForwardPE": "-", "PriceToSalesRatioTTM": "-", "PriceToBookRatio": "1.129", "EVToRevenue": "-", "EVToEBITDA": "-0.0842", "Beta": "0.239", "52WeekHigh": "2.06", "52WeekLow": "0.614", "50DayMovingAverage": "1.532", "200DayMovingAverage": "1.133", "SharesOutstanding": "14524100", "SharesFloat": "14594600", "PercentInsiders": "2.903", "PercentInstitutions": "3.729", "DividendDate": "None", "ExDividendDate": "None"}